Hyundai ADM Biotech's Penetrium shows anti─metastatic effect in triple─negative breast cancer preclinical study
Hyundai ADM Biotech has announced that its first-in-class pseudo-resistance-targeting agent, Penetrium, showed significant anti-metastatic efficacy in a preclinical study on triple-negative breast cancer (TNBC). Detailed results presented at the 2025 …